Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESS-Reference-Cited by-同舟云学术

Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESS

Published:2018-04-05 Issue:10 Volume:20 Page:1261-1267
ISSN:1699-048X
Container-title:Clinical and Translational Oncology
language:en
Short-container-title:Clin Transl Oncol

Author:

Arriola E.^ORCID,Paredes-Lario A.,García-Gomez R.,Diz-Tain P.,Constenla M.,García-Girón C.,Márquez G.,Reck M.,López-Vivanco G.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/article/10.1007/s12094-018-1855-y/fulltext.html

Reference36 articles.

1. National Cancer Institute. SEER cancer statistics review, 1975–2012. http://seer.cancer.gov/csr/1975_2012/ . Accessed 6 Jul 2016.

2. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–57.

3. Dearden S, Stevens J, Wu YL, Blowers D. Mutation incidence and coincidende in NSCLC: meta-analyses by ethnicity and histology (mutMap). Ann Oncol. 2013;24:2371–6.

4. García-Campelo R, Bernabé R, Cobo M, Corral J, Coves J, Dómine M, et al. SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015. Clin Transl Oncol. 2015;17:1020–9.

5. Esteban E, Majem M, Martinez Aguillo M, Martinez Banaclocha N, Dómine M, Gómez Aldaravi L, et al. Prevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: the Spanish REASON study. Cancer Epidemiol. 2015;39:291–7.

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of Confirmed Cytology Smears and Cell Blocks for Epidermal Growth Factor Receptor Mutation Testing in Non–Small Cell Lung Cancer;Applied Immunohistochemistry & Molecular Morphology;2023-10-09

2. EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast;Targeted Oncology;2023-10-04

3. Evaluation of the Analytical Performance of Oncomine Lung cfDNA Assay for Detection of Plasma EGFR Mutations;Genes;2023-06-02

4. Efficacy of liquid biopsy for disease monitoring and early prediction of tumor progression in EGFR mutation-positive non-small cell lung cancer;PLOS ONE;2022-04-28

5. Concordance of Epidermal Growth Factor Receptor Mutation from Tissue Biopsy and Plasma Circulating Tumor DNA in Treatment-Naïve Lung Adenocarcinoma Patients;Open Access Macedonian Journal of Medical Sciences;2022-03-25